Physician profile
Mark A Bonner
NPI 1437188869
$11,221.93
in general payments reported to CMS, 2019-2025
64 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $2,154 · 2021: $1,994 · 2022: $1,477 · 2023: $1,768 · 2024: $1,216 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,499.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,219.26 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,215.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,159.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $562.45 | 2019-2020 | |
| Abbott Laboratories | $554.79 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $532.57 | 2019-2023 | |
| Novo Nordisk INC | $458.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $365.78 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $314.99 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $310.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $272.02 | 2023-2025 | Sotyktu |
| Sunovion Pharmaceuticals INC. | $209.51 | 2020-2022 | |
| Amgen INC. | $197.08 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $180.78 | 2019-2025 | |
| Esperion Therapeutics, INC. | $175.17 | 2020-2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.